Pharmacological and functional characterization of novel EP and DP receptor agonists: DP1 receptor mediates penile erection in multiple species

Journal of Sexual Medicine

Volumn 5, Issue 2, 2008, Pages 344-356

  Brugger, Nadia ^a   Kim, Noel N ^b   Araldi, Gian Luca ^a   Traish, Abdulmaged M ^b   Palmer, Stephen S ^a  

^a EMD SERONO INC   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Organ bath; Prostaglandin D2; Prostaglandin E1

Indexed keywords

5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; AS 701666; AS 701715; AS 701724; AS 701740; AS 701753; AS 701766; AS 701919; AS 701931; AS 702224; PROSTAGLANDIN D1 RECEPTOR; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2 DERIVATIVE; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; CORRELATION COEFFICIENT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SPECIFICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIGAND BINDING; LOW DRUG DOSE; MALE; MUSCLE TONE; NONHUMAN; PENILE BLOOD FLOW; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RABBIT; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; VASODILATATION;

EID: 38649112588     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00676.x     Document Type: Article

References (33)

1. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004;36:1187-205.
2. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther 2004;103:147-66.
3. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
4. Saenz de Tejada I, Angulo J, Cellek S, Gonzalez-Cadavid N, Heaton J, Pickard R, Simonsen U. Physiology of erectile function. J Sex Med 2004;1:254-65.
5. Daley JT, Brown ML, Watkins T, Traish AM, Huang YH, Moreland RB, De Tejada IS. Prostanoid production in rabbit corpus cavernosum: I. Regulation by oxygen tension. J Urol 1996;155:1482-7.
6. Moreland RB, Albadawi H, Bratton C, Patton G, Goldstein I, Traish A, Watkins MT. O2-dependent prostanoid synthesis activates functional PGE receptors on corpus cavernosum smooth muscle. Am J Physiol 2001;281:H552-8.
7. Moreland RB, Nehra A, Kim NN, Min KS, Albadawi H, Watkins MT, Goldstein I, Traish AM. Expression of functional prostaglandin D (DP) receptors in human corpus cavernosum smooth muscle. Int J Impot Res 2002;14:446-52.
8. Angulo J, Cuevas P, La Fuente JM, Pomerol JM, Ruiz-Castañé E, Puigvert A, Gabancho S, Fernández A, Ney P, Sáenz de Tejada I. Regulation of human penile smooth muscle tone by prostanoid receptors. Br J Pharmacol 2002;136:23-30.
9. Komuro M, Kamiyama M, Furuya Y, Takihana Y, Araki I, Takeda M. Gene and protein expression profiles of prostaglandin E2 receptor subtypes in the human corpus cavernosum. Int J Impot Res 2006;18:275-81.
10. Moreland RB, Kim N, Nehra A, Goldstein I, Traish A. Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int J Impot Res 2003;15:362-8.
11. 4 receptors. Eur J Pharmacol 2004;501:49-58.
12. Lin JS, Lin YM, Jou YC, Cheng JT. Role of cyclic adenosine monophosphate in prostaglandin E1-induced penile erection in rabbits. Eur Urol 1995;28:259-65.
13. Lin YM, Lin JS. The rabbit as an intracavernous injection study model. Urol Res 1996;24:27-32.
14. Buvat J, Costa P, Morlier D, Lecocq B, Stegmann B, Albrecht D. Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol 1998;159:116-9.
15. Fulgham PF, Cochran JS, Denman JL, Feagins BA, Gross MB, Kadesky KT, Kadesky MC, Clark AR, Roehrborn CG. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998;160:2041-6.
16. Lea AP, Bryson HM, Balfour JA. Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Drugs Aging 1996;8:56-74.
17. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334:873-7.
18. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1-7.
19. Costabile RA, Spevak M, Fishman IJ, Govier FE, Hellstrom WJ, Shabsigh R, Nemo KJ, Rapport JL, Tam PY, Weldon KL, Gesundheit N. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998;160:1325-8.
20. Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, Kim JJ, Zhi-Zhou S, Israr D, Niazi D, Rajatanavin R, Suyono S, Benard F, Casey R, Brock G, Belanger A. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001;13:317-21.
21. Lane BR, Ausmundson SJ, Butler RS, Zippe CD, Jones JS, Lakin MM. Use of a visual analog scale to assess pain of injection with intracavernous injection therapy. J Sex Med 2005;2:428-31.
22. Tsai YS, Lin JS, Lin YM. Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction. Eur Urol 2000;38:177-83.
23. Ferreira SH, Nakamura MI. Prostaglandin hyperalgesia, a cAMP/Ca2+ dependent process. Prostaglandins 1979;18:179-90.
24. Khasar SG, Ho T, Green PG, Levine JD. Comparison of prostaglandin E1- and prostaglandin E2-induced hyperalgesia in the rat. Neuroscience 1994;62:345-50.
25. Khasar SG, Ouseph AK, Chou B, Ho T, Green PG, Levine JD. Is there more than one prostaglandin E receptor subtype mediating hyperalgesia in the rat hindpaw? Neuroscience 1995;64:1161-5.
26. Mashimo T, Pak M, Choe H, Inagaki Y, Yamamoto M, Yoshiya I. Effects of vasodilators guanethidine, nicardipine, nitroglycerin, and prostaglandin E1 on primary afferent nociceptors in humans. J Clin Pharmacol 1997;37:330-5.
27. Minami T, Nakano H, Kobayashi T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Ito S. Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br J Pharmacol 2001;133:438-44.
28. Omote K, Kawamata T, Nakayama Y, Kawamata M, Hazama K, Namiki A. The effects of peripheral administration of a novel selective antagonist for prostaglandin E receptor subtype EP(1), ONO-8711, in a rat model of postoperative pain. Anesth Analg 2001;92:233-8.
29. Ouseph AK, Khasar SG, Levine JD. Multiple second messenger systems act sequentially to mediate rolipram-induced prolongation of prostaglandin E2-induced mechanical hyperalgesia in the rat. Neuroscience 1995;64:769-76.
30. Stock JL, Shinjo K, Burkhardt J, Roach M, Taniguchi K, Ishikawa T, Kim HS, Flannery PJ, Coffman TM, McNeish JD, Audoly LP. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 2001;107:325-31.
31. Wang JF, Khasar SG, Ahlgren SC, Levine JD. Sensitization of C-fibres by prostaglandin E2 in the rat is inhibited by guanosine 5′-O-(2-thiodiphosphate), 2′,5′-dideoxyadenosine and Walsh inhibitor peptide. Neuroscience 1996;71:259-63.
32. Minami T, Okuda-Ashitaka E, Mori H, Ito S, Hayaishi O. Prostaglandin D2 inhibits prostaglandin E2-induced allodynia in conscious mice. J Pharmacol Exp Ther 1996;278:1146-52.
33. Minami T, Okuda-Ashitaka E, Nishizawa M, Mori H, Ito S. Inhibiton of nociception-induced allodynia in conscious mice by prostaglandin D2. Br J Pharmacol 1997;122:605-10.